Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1

Conditions

Solid Tumor 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × ensartinib × Clear all
NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT03510611 2019-07-24

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03536481 2019-07-24

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
74 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡